Literature DB >> 7528711

Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion.

C M Fernández-Rodriguez1, J Prieto, J Quiroga, J M Zozoya, A Andrade, M Núñez, B Sangro, J Penas.   

Abstract

The mediators of the hyperdynamic circulation of liver cirrhosis are not well characterized. Substance P is a potent vasodilatory peptide produced by the enteric nervous system and partly cleared by the liver. In this work we have investigated the plasma levels of substance P and their relationship to the hemodynamic, neurohormonal, and renal function changes occurring in patients with cirrhosis. Seven healthy subjects (control group), 7 cirrhotic patients without ascites (group I), and 24 cirrhotic patients with ascites (group II) were studied. Cardiac output (CO), femoral blood flow (FBF), blood volume (BV), femoral arteriovenous difference of oxygen content (Ca-v O2), plasma renin activity (PRA), plasma aldosterone concentration (PAC), and plasma norepinephrine (NE) were determined. Five patients underwent trans-jugular intrahepatic porto-systemic stent shunt (TIPSS) because of refractory ascites. Immunoreactive substance P (irSP) was measured by radioimmunoassay after plasma extraction. irSP was higher in ascitic patients than in healthy controls (P < .01) and directly correlated with PRA, PAC, plasma NE, and Pugh's score and was inversely correlated with urinary sodium excretion, glomerular filtration rate, and Ca-v O2. No differences were observed between portal and peripheral vein irSP concentration. TIPSS placement induced a decrease in portal pressure and an increase in CO but circulating irSP remained unchanged. Our data show that circulating irSP is increased in decompensated cirrhotic patients and may be involved in the pathogenesis of the hemodynamic changes of cirrhosis. Alleviation of portal hypertension did not result in decreased plasma levels of this vasodilatory substance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528711     DOI: 10.1002/hep.1840210108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

3.  Measurement of plasma-derived substance P: biological, methodological, and statistical considerations.

Authors:  Donald E Campbell; Nancy Raftery; Richard Tustin; Nancy B Tustin; Michelle L Desilvio; Avital Cnaan; Pyone Pyone Aye; Andrew A Lackner; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2006-09-13

4.  Development and evaluation of a chromatographic procedure for partial purification of substance P with quantitation by an enzyme immunoassay.

Authors:  W P Fehder; W Z Ho; D E Campbell; W W Tourtellotte; L Michaels; J R Cutilli; M Uvaydova; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

5.  Enhanced urinary excretion of cGMP in liver cirrhosis. Relationship to hemodynamic changes, neurohormonal activation, and urinary sodium excretion.

Authors:  C M Fernández-Rodriguez; J Prieto; J Quiroga; J M Zozaya; A Andrade; C Rodriguez-Ortigosa
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 6.  New determinants of prognosis in bacterial infections in cirrhosis.

Authors:  Juan Acevedo; Javier Fernández
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension.

Authors:  V Tahan; E Avsar; C Karaca; E Uslu; F Eren; S Aydin; H Uzun; H O Hamzaoglu; F Besisik; C Kalayci; A Okten; N Tozun
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

8.  Novel method for determination of substance P levels in unextracted human plasma by using acidification.

Authors:  Donald E Campbell; Paula Bruckner; Nancy B Tustin; Richard Tustin; Steven D Douglas
Journal:  Clin Vaccine Immunol       Date:  2009-02-04

Review 9.  New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.

Authors:  Leonardo Lorente
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

10.  Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality.

Authors:  Leonardo Lorente; Sergio T Rodriguez; Pablo Sanz; Antonia Pérez-Cejas; Javier Padilla; Dácil Díaz; Antonio González; María M Martín; Alejandro Jiménez; Purificación Cerro; Manuel A Barrera
Journal:  Oncotarget       Date:  2018-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.